Lomustine®
An antineoplastic alkylating agent from the nitrosourea group.
Indications
Lomustine is used as monotherapy or in combination therapy (including in combination with radiation therapy and surgery) for the treatment of:
- primary and metastatic brain tumors;
- lung cancer (especially small-cell lung cancer);
- Hodgkin’s disease resistant to standard chemotherapy;
- malignant metastatic melanoma.
Lomustine may also be used in the treatment of:
- multiple myeloma, gastric and intestinal cancer, renal cancer.
Dosage form
Capsules, 40 mg.
Age restrictions
Adults and children.
Dosage regimen
- The recommended dose of lomustine in adults and children with normal bone marrow function is 120–130 mg/m² as a single oral dose every 6–8 weeks.
- This dose may be divided into three doses administered over three consecutive days.
- In patients with impaired bone marrow function, the single dose may be reduced to 100 mg/m² while maintaining the 6-week dosing interval.
Manufacturing and Registration
Manufacturer: N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, 115478, Moscow, Kashirskoe Highway, 24, bldg. 2, «Naukoprofi» branch.
Legal entity holding the marketing authorization: Nanolek LLC, 123112, Moscow, Presnensky Municipal District, Testovskaya St., 10, premises 1/16. Tel.: +7 495 648-26-87, Email: info@nanolek.ru.